These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37144597)

  • 1. Early changes of fecal short-chain fatty acid levels in patients with mild cognitive impairments.
    Gao C; Li B; He Y; Huang P; Du J; He G; Zhang P; Tang H; Chen S
    CNS Neurosci Ther; 2023 Nov; 29(11):3657-3666. PubMed ID: 37144597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography.
    Li Y; Yao Z; Yu Y; Zou Y; Fu Y; Hu B;
    BMC Psychiatry; 2019 Jun; 19(1):165. PubMed ID: 31159754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Zhang N; Zhang L; Li Y; Gordon ML; Cai L; Wang Y; Xing M; Cheng Y
    J Alzheimers Dis; 2017; 60(1):87-95. PubMed ID: 28777752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
    Chen SJ; Chen CC; Liao HY; Lin YT; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
    Neurology; 2022 Feb; 98(8):e848-e858. PubMed ID: 34996879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Amyloid Pathology in Mild Cognitive Impairment Subjects: The Longitudinal Cognition and Surface Morphometry Data.
    Chang HI; Hsu SW; Kao ZK; Lee CC; Huang SH; Lin CH; Liu MN; Chang CC
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.
    Bangen KJ; Clark AL; Werhane M; Edmonds EC; Nation DA; Evangelista N; Libon DJ; Bondi MW; Delano-Wood L;
    J Alzheimers Dis; 2016 Mar; 52(3):849-61. PubMed ID: 27031472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids.
    Yang X; Ai P; He X; Mo C; Zhang Y; Xu S; Lai Y; Qian Y; Xiao Q
    Mov Disord; 2022 Aug; 37(8):1634-1643. PubMed ID: 35607987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
    Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ;
    Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson's Disease.
    Oh YS; Yoo SW; Lyoo CH; Yoo JY; Yoon H; Ha S; Lee KS; Kim JS
    J Parkinsons Dis; 2021; 11(2):605-613. PubMed ID: 33646180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Radiomic Features as New Biomarkers for Alzheimer's Disease: An Amyloid PET Study.
    Ding Y; Zhao K; Che T; Du K; Sun H; Liu S; Zheng Y; Li S; Liu B; Liu Y;
    Cereb Cortex; 2021 Jul; 31(8):3950-3961. PubMed ID: 33884402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.